TLR3 and neoplasm: This study being led by Brody and colleagues has shown that this vaccine strategy induces successful antigen cross-presentation in TLR3+ DCs of tumor microenvironment and subsequent tumor regression in a clinical trial of indolent non-Hodgkin’s lymphoma [103].